An expert's take on the most clinically relevant reports from this year's resistance meeting
In June 2012, researchers and physicians from around the world gathered in Sitges, Spain, for the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Below is a summary of the most clinically compelling presentations with respect to HIV medicine. (The entire abstract book is available in a supplement of Antiviral Therapy.)
Resistance to Integrase Inhibitors: Raltegravir, Elvitegravir, and Dolutegravir
Elvitegravir is an investigational integrase inhibitor currently being evaluated by the FDA, both individually and as part of the coformulated Quad pill. Previous studies identified six positions in integrase that are important for elvitegravir resistance, several of which are also important for raltegravir a…